



**STATE PROCUREMENT OFFICE  
NOTICE & REQUEST FOR SOLE SOURCE**

12 APR 16 10:57

STATE PROCUREMENT OFFICE  
STATE OF HAWAII

TO: Chief Procurement Officer

FROM: State Laboratories Division, Department of Health  
*Name of Requesting Department*

Pursuant to HRS §103D-306 and HAR chapter 3-122, Subchapter 9, the Department requests sole source approval to purchase the following:

1. Describe the goods, services, or construction to be procured.  
One unit Applied Biosystems 3500xL Genetic Analyzer with pre-packaged consumables, Genetic Analyzer installation kit, Reference E328890 for UL and cUL Approval, C-tick approval, installation and training by qualified engineer, one-year service warranty on hardware parts and labor, and technical support ( phone and internet).

2. Vendor/Contractor/Service Provider Name: Applied Biosystems, part of Life Technologies	3. Amount of Request: \$165,000.00
4. Term of contract (shall not exceed 12 months), if applicable: From: upon approval To: 1 year from approval date	5. Prior SPO-001, Sole Source (SS) No.:

6. Describe in detail the following:

a. The unique features, characteristics, or capabilities of the goods, service or construction.  
The ABI 3500 xL genetic Analyzer allows 24 samples/run ; it features a novel solid-state laser technology that reduces the physical and environmental footprint of the instrument. As a result, the unit needs less space and generates less heat than the older generation of ABI 31130 xL that we currently have. Because of the solid-state laser feature of this ABI 3500 xL, the unit can be plugged in any outlet and does not need a special heat-ducting infrastructure that the older generation analyzer requires. More importantly, the system has longer life than a gas-laser technology- feature of the older generation ABI 3130xL.

b. How the unique features, characteristics or capabilities of the goods, service or construction are essential for the department to accomplish its work.  
Since the new ABI 3500 xL genetic Analyzer allows 24 samples/run , the Turn-Around-Time (TAT) for sequence analysis ( for bacterial identification, norovirus sequence analysis, Multi-Locus Variable Tandem Number repeats Assay (MLVA) , to name a few of the applications for this instrument) is reduced from 16 samples for 4 hours to 24 samples in 4 hours. Moreover, the State Lab purchased a \$20,000.00 software program( Microseq) for bacterial identification that we have validated and used for the older generation ABI 3130xL platform that can be transferred and used for this unit. Finally, the SOP for norovirus sequence analysis that was validated for the ABI 3130xL and the MLVA can also be used to evaluate the performance of this platform. Our staff has achieved competency and maintained their proficiency in using the ABI Genetic Analyzer platform for Microseq bacterial identification, norovirus sequence analysis, and MLVA and these competencies are directly transferrable to the newer ABI 3500xL platform.

6879

7. Describe the efforts and results in determining that this is the only vendor/contractor/service provider who can provide the goods, services or construction.

The patented technology incorporated in the ABI 3500 xL Genetic Analyzer is owned and under the control of Applied Biosystems. This instrument and consumables can only be purchased from the Applied Biosystems and the company has been certified as compliant with the HI Compliance Express.

8. Alternate source. Describe the other possible sources for the goods, services, or construction that were investigated but did not meet the department's needs.

We have investigated Beckman Coulter but for the following reasons, we are staying with the ABI 3500xL genetic Analyzer: 1. It has a lower throughput ( 8 capillary = 8 samples per run) than the ABI 3500xL ( 24 capillaries = 24 samples per run). 2. Proficiency and competencies of the staff acquired from 10 years of experience using the ABI 3130 platform is not transferrable to the Beckman platform. 3. The \$20K Microseq program that we currently use for Bacterial Identification cannot be used in the Beckman platform. 4. The validated method for Norovirus sequence analysis and MLVA cannot be transferred to the Beckman platform. 5. Beckman does not have a validated microbial identification database while the ABI has the Microseq ( that we currently use).

9. Identify the primary individual(s) who is knowledgeable about this request, who will conduct and manage this process, and has 1) appropriate written delegated procurement authority; 2) completed mandatory training; and 3) who SPO may contact for follow up inquiry, if any.

(Type over "example" and delete cells not used.)

Name of Department Personnel	Division/Agency	Phone Number	E-mail Address
Rebecca Sciulli	State Lab Division	453-5993	rebecca.sciulli@doh.hawaii.gov

Department shall ensure adherence to applicable administrative and statutory requirements, including HAR chapter 3-122, Subchapter 15, Cost or Pricing Data if required.

**All requirements/approvals and internal controls for this expenditure is the responsibility of the department.  
I certify that the information provided is to the best of my knowledge, true and correct.**

  
\_\_\_\_\_  
Department Head Signature

  
\_\_\_\_\_  
Date

**For Chief Procurement Officer Use Only**

Date Notice Posted: 4/17/2012

Submit written objection to this notice to issue a sole source contract within seven calendar days or as otherwise allowed from date notice posted to:

state.procurement.office@hawaii.gov

Chief Procurement Officer (CPO) Comments:

Approval is granted based on the department's representation that the manufacturer's equipment is essential for their work and available from only this vendor. Sole source contracts in excess of \$100,000 require cost or pricing data pursuant to HAR chapter 3-122, subchapter 15. This approval is for the solicitation process only, HRS section 103D-310(c) and HAR section 3-122-112, shall apply (i.e. vendor is required to be compliant on the Hawaii Compliance Express) and award is required to be posted on the Awards Reporting System.

If there are any questions, please contact Bonnie Kahakui at 587-4702, or [bonnie.a.kahakui@hawaii.gov](mailto:bonnie.a.kahakui@hawaii.gov).

Approved

Disapproved

No Action Required

Adams. Fuji      4/25/2012  
Chief Procurement Officer Signature      Date

Addendum to: SPO -001 – ABI 3500 xL genetic Analyzer

Unique feature of the ABI 3500 xL genetic Analyzer:

- The ABI 3130 xL Genetic Analyzer that we currently use will be discontinued and will be replaced by this model.
- A software program (Microseq 16 S Bacterial Identification System) was developed specifically for the ABI Genetic Analyzer and the current/updated version of this software will be installed to the 3500xL Model. This software program is not transferrable to any other genetic Analyzer and is proprietary to ABI.
- As one of the 17 CaliciNet laboratories in the USA, our lab is responsible for sharing sequence information and genotyping of norovirus strains. The norovirus sequence analysis protocol that was developed by the CDC has been validated on the ABI Genetic Analyzer and will be migrated easily to the ABI 3500xL model. Using the protocol developed by the CDC allows us to exchange information electronically, allowing laboratories and epidemiologists throughout the United States to rapidly compare sequences of submitted strains with those in the national CaliciNet database. The ability to compare strains quickly leads to more rapid detection of, potentially multistate, outbreaks as well as faster response time by public health agencies, contributing to the improved prevention of additional foodborne illnesses.
- We have also used the ABI Genetic Analyzer to validate another CDC molecular subtyping method that provides a better and more sensitive way of characterizing pathogenic bacteria. We have been working on this method for almost 1 year now and have spent man-hours and resources to establish this test- Multi-Locus Variable Tandem repeats assay (MLVA) as part of our federal funding deliverable. It will be prudent for us to maintain this protocol on the ABI to ensure future funding from the CDC.